Last updated: July 17, 2026

Application No. 18/687,347

Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof

Non-Final OA

Filed

Feb 28, 2024

Priority

Aug 30, 2021 — provisional 63/238,337 +3 more

Examiner

VALENROD, YEVGENY

Art Unit

1628

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Amgen Inc.

OA Round

1 (Non-Final)

Interview Optional

— +25.5% interview lift. Examiner has a relatively high allowance rate (72%); +25.5% interview lift. A written response may suffice.

Based on 1012 resolved cases, 2023–2026

Examiner Intelligence

VALENROD, YEVGENY View full profile →

Grants 72% — above average

Career Allowance Rate

734 granted / 1012 resolved

+12.5% vs TC avg

Strong +26% interview lift

Without

With

+25.5%

Interview Lift

resolved cases with interview

Typical timeline

2y 6m

Avg Prosecution

38 currently pending

Career history

1049

Total Applications

across all art units

Statute-Specific Performance

§101

1.1%

-38.9% vs TC avg

§103

48.6%

+8.6% vs TC avg

§102

13.4%

-26.6% vs TC avg

§112

7.7%

-32.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1012 resolved cases

Prosecution Timeline

Feb 28, 2024

Application Filed

Apr 22, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/917,194

Patent 12661355

COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION

3y 8m to grant Granted Jun 23, 2026

17/839,169

Patent 12611402

COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY

3y 10m to grant Granted Apr 28, 2026

18/057,918

Patent 12611391

MATERIALS AND METHODS FOR IMPROVING LUNG FUNCTION AND FOR PREVENTION AND/OR TREATMENT OF RADIATION-INDUCED LUNG COMPLICATIONS

3y 5m to grant Granted Apr 28, 2026

17/782,441

Patent 12605374

METHODS FOR DRUG SCREENING AND COMPOSITIONS USEFUL FOR THE INHIBITION OF CELL PROLIFERATION AND/OR CELL SURVIVAL

3y 10m to grant Granted Apr 21, 2026

18/027,990

Patent 12590100

TETRAHYDRO-SPIROINDOLINE-PYRROLOPYRROLE-TRIONES INHIBITORS OF THE NRF2-BETA-TRCP INTERACTION FOR USE IN THE TREATMENT OF FATTY LIVER DISEASE

3y 0m to grant Granted Mar 31, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

72%

Grant Probability

98%

With Interview (+25.5%)

2y 6m (~1m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1012 resolved cases by this examiner. Grant probability derived from career allowance rate.